电脑药物发现的全球市场：市场规模和占有率分析 - 趋势、驱动因素、竞争格局、未来预测（2024-2030）

市场概况

2023 年，全球电脑模拟药物发现市场收入为 28.297 亿美元，预计到 2030 年将达到 56.914 亿美元，预测期内复合年增长率为 10.6%。 该行业的成长是由对减少用药错误的日益关注、计算生物学的技术进步以及基于云端的药物发现的日益使用所推动的。

此外，计算生物学的进步以及定序的分析阶段正在促进数据处理的简化，从而缩短週转时间并获得更准确的结果。 所有这些增强功能正在推动灵活节点优化和储存整合的新趋势，主要行业领导者都在关注这一趋势。

云端控制软体的日益普及是推动电脑模拟药物发现市场成长的主要因素之一。 云端运算提供了几乎无限的运算资源的机会，使药物研究人员能够获得适合其需求的运算能力。

关键见解

2023 年，人工智慧 (AI) 类别以超过 65% 的占有率引领市场。 这是由医疗保健数据数位化程度不断提高所推动的。

SaaS 类别预计将以约 10.8% 的复合年增长率成长。

预计 CRO（合约研究组织）在预测期内的复合年增长率将超过 11.0%，从而降低公司的药物开发成本。

依地区划分，到 2023 年，北美将占全球电脑模拟药物发现产业占有率的 50%。 这是由罕见疾病治疗的需求以及生物製药公司增加的研发投资所推动的。

在美国，医疗和研发投资大幅扩张，2020年达到约2,500亿美元，为产业成长做出了贡献。

在旨在改善患者健康的努力的推动下，亚太地区的电脑药物发现产业取得了显着的发展，主要是在基于软体的技术方面。

本报告分析了全球电脑模拟药物发现市场，包括市场的基本结构和最新情况、主要促进和限制因素以及全球、依地区和主要国家（以货币形式计算）的市场规模前景，2017-2030 ），依产品、工作流程、应用程式和最终用户划分的详细趋势、市场竞争的现状以及主要公司的概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第六章世界市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依工作流程分类（2017-2030 年）
• 市场收入：依技术划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依地区划分（2017-2030 年）

第七章北美市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依工作流程分类（2017-2030 年）
• 市场收入：依技术划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第十一章中东及非洲市场

第12章美国市场

• 摘要
• 市场收入：依产品分类（2017-2030 年）
• 市场收入：依工作流程分类（2017-2030 年）
• 市场收入：依技术划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其提供的产品/服务的列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• chrodinger Inc.
• Dassault Systemes
• OpenEye Scientific Software
• Chemical Computing Group
• Cresset Biomolecular Discovery Limited
• Insilico Medicine
• Atomwise Inc.
• Evotec
• Charles River Laboratories
• Ligand Pharmaceuticals Incorporated
• Simulation Plus

第31章附录

Market Overview

The worldwide in-silico drug discovery produced a revenue of USD 2,829.7 million in 2023 and is projected to touch USD 5,691.4 million by 2030, growing at a CAGR of 10.6% over the projection period. The development of the industry can be credited to the growing emphasis on decreasing medication mistakes, technical improvements in computational biology, and the rising use of cloud-based applications in drug discovery.

The worldwide in-silico drug discovery market is also propelled by the fast technical advances in the field of computational biology. Computational methods have been effective in the growth of new medicinal molecules.

In addition, advances in computational biology facilitate the simplification of data processing along with analysis phases of sequencing producing shorter turnaround times and accurate results. All the enhancements have triggered a new trend of flexible node optimization and storage integration that major industry leaders are looking into.

Such integration is expected to decrease the amount of transfer data and to solve the queues in data processing, which in principle will eliminate the downlink from the computational analytical community to the ground.

The growing prevalence of cloud control software is one of the main forces driving the in-silico drug discovery market growth. Researchers who study pharmaceuticals can secure access to the amount of computational power that meets their needs because cloud computing provides the opportunity to get almost unlimited computational resources.

Key Insights

In 2023, the AI category led the market with more than 65% share, propelled by augmented data digitization in health care.

Artificial intelligence confronts issues like analyzing multifaceted clinical difficulties and quickening therapeutic target validation in medication discovery.

It helps in the designing of drugs, chemical synthesis, monitoring, polypharmacology, and repurposing, making it essential to numerous stages of drug advancement.

The SaaS category is estimated to advance at a CAGR of around 10.8% in the in-silico drug discovery industry.

Acceptance of SaaS aids in reducing prices and time taken in drug discovery procedures.

SaaS channels are extensively utilized for virtual screening and aim fishing in drug discovery.

Contract Research Organizations are projected to advance at a CAGR of more than 11.0% during the projection period, decreasing costs for businesses in drug development.

Working with a contract research organization provides sponsors not only with an advantage over the traditional clinical studies but also with a quick opportunity to obtain an entire package of trial solutions for the studies to be successful.

The computer application with the largest market resource was introduced in 2021, commonly used for new drug medication designing and in ADME-tox modeling and off-target prediction.

Pharmacophore systematics is usually used concurrently with molecular docking simulations in order to improve the efficiency of virtual screening assays.

In 2023, the North American region help 50% of the worldwide in-silico drug discovery industry share, boosted by the need for treatments for rare illnesses and augmented research and development investments by biopharmaceutical businesses.

The U.S. experienced substantial development in medical and research and development investments, attaining around USD 250 billion in 2020, contributing to industry growth.

The APAC in-silico drug discovery industry has witnessed prominent development, mainly in software-based techs, reinforced by initiatives aimed at advancing patient health.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by workflow
  • 1.4.3. Market size breakdown, by technology
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Workflow (2017-2030)
• 6.4. Market Revenue, by Technology (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Workflow (2017-2030)
• 7.4. Market Revenue, by Technology (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Workflow (2017-2030)
• 8.4. Market Revenue, by Technology (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Workflow (2017-2030)
• 9.4. Market Revenue, by Technology (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Workflow (2017-2030)
• 10.4. Market Revenue, by Technology (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Workflow (2017-2030)
• 11.4. Market Revenue, by Technology (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Workflow (2017-2030)
• 12.4. Market Revenue, by Technology (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Workflow (2017-2030)
• 13.4. Market Revenue, by Technology (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Workflow (2017-2030)
• 14.4. Market Revenue, by Technology (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Workflow (2017-2030)
• 15.4. Market Revenue, by Technology (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Workflow (2017-2030)
• 16.4. Market Revenue, by Technology (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Workflow (2017-2030)
• 17.4. Market Revenue, by Technology (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Workflow (2017-2030)
• 18.4. Market Revenue, by Technology (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Workflow (2017-2030)
• 19.4. Market Revenue, by Technology (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Workflow (2017-2030)
• 20.4. Market Revenue, by Technology (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Workflow (2017-2030)
• 21.4. Market Revenue, by Technology (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Workflow (2017-2030)
• 22.4. Market Revenue, by Technology (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Workflow (2017-2030)
• 23.4. Market Revenue, by Technology (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Workflow (2017-2030)
• 24.4. Market Revenue, by Technology (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Workflow (2017-2030)
• 25.4. Market Revenue, by Technology (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Workflow (2017-2030)
• 26.4. Market Revenue, by Technology (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Workflow (2017-2030)
• 27.4. Market Revenue, by Technology (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Workflow (2017-2030)
• 28.4. Market Revenue, by Technology (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. chrodinger Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Dassault Systemes
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. OpenEye Scientific Software
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Chemical Computing Group
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Cresset Biomolecular Discovery Limited
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Insilico Medicine
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Atomwise Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Evotec
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Charles River Laboratories
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Ligand Pharmaceuticals Incorporated
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Simulation Plus
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports